Stockreport

Vir Biotechnology (VIR) Up on Positive Data From HDV Study [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF The study is evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta. Tobevibart [Read more]